Please assess the completion status of the following clinical trial:

Trial Title: Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~  * Stage I, II, or IIIA disease~* Completed ≤ 6 years of adjuvant tamoxifen therapy~* Total baseline lumbar spine or femoral neck bone mineral density T-score below -2.0 standard deviation (e.g., a patient with a T-score of -2.1 in ineligible; a patient with a T-score of -1.9 is eligible)~* No clinical or radiological evidence of recurrent or metastatic disease~* Hormone receptor status:~  * Estrogen receptor- and/or progesterone receptor-positive~PATIENT CHARACTERISTICS:~Age~* Postmenopausal~Sex~* Female~Menopausal status~* Postmenopausal, defined by 1 of the following:~  * Over 55 years of age with cessation of menses~ * 55 years of age and under with spontaneous cessation of menses for \> 1 year~ * 55 years of age and under with spontaneous cessation of menses for ≤ 1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy) with postmenopausal estradiol levels (\< 5 ng/dL)~ * Undergone bilateral oophorectomy~Performance status~* ECOG 0-2~Life expectancy~* At least 5 years~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~Renal~* Creatinine \< 2.0 mg/dL~* No hypercalcemia (i.e., calcium \> 1 mg/dL above ULN within the past 6 months)~* No hypocalcemia (i.e., calcium \> 0.5 mg/dL below lower limit of normal within the past 6 months)~Other~* No uncontrolled infection~* No uncontrolled diabetes mellitus~* No uncontrolled thyroid dysfunction~* No disease affecting bone metabolism (e.g., hyperparathyroidism, hypercortisolism, Paget's disease, or osteogenesis imperfecta)~* No malabsorption syndrome~* No uncontrolled seizure disorder associated with falls~* No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or cholecalciferol (vitamin D)~* No mental illness that would preclude giving informed consent~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No other non-malignant systemic disease~* No clinical or radiologic evidence of existing fracture in the lumbar spine and/or total hip~* No history of fracture with low intensity or not associated with trauma~* No contraindication to spinal dual energy x-ray absorptiometry (DEXA) due to any of the following:~  * History of surgery at the lumbosacral spine, with or without implantable devices~ * Scoliosis with a Cobb angle \> 15° at the lumbar spine~ * Immobility, hyperostosis, or sclerotic changes at the lumbar spine~ * Evidence of sufficient sclerotic abdominal aorta that would interfere with DEXA scan~ * Any disease of the spine that would preclude proper acquisition of a lumbar spine DEXA~* Considered reliable~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No concurrent chemotherapy~Endocrine therapy~* See Disease Characteristics~* Prior parathyroid hormone allowed provided it was not administered for \> 1 week~* More than 6 months since prior anabolic steroids or growth hormone~* More than 12 months since prior endocrine therapy (including estrogen) except for the following:~  * Tamoxifen~ * Insulin~ * Oral hypoglycemics~ * Thyroid hormone~ * Steroid inhalers~* More than 12 months since prior systemic corticosteroids except short-term corticosteroids to prevent or treat chemotherapy-induced nausea and vomiting or acute respiratory illness~  * Concurrent short-term corticosteroids allowed~* No other concurrent hormonal therapy~* No concurrent parathyroid hormone~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* Prior systemic sodium fluoride allowed provided it was not administered for \> 3 months within the past 2 years~* More than 3 weeks since prior oral bisphosphonates~* More than 2 weeks since prior and no concurrent drugs known to affect the skeleton (e.g., calcitonin, mithramycin, or gallium nitrate)~* More than 30 days since prior systemic investigational drugs and/or devices~* More than 7 days since prior topical investigational drugs~* No prior IV bisphosphonates~* No prior aromatase inhibitor therapy~* No concurrent calcitonin, sodium fluoride, or Tibolone~* No other concurrent anticancer therapy~* No other concurrent bisphosphonates~* No other concurrent investigational drugs or devices

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: letrozole + zoledronate (Type: EXPERIMENTAL): Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
- Arm II: letrozole + zoledronate (Type: EXPERIMENTAL): Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).